GOODWILL - Impairment Testing (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Dec. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
Goodwill [Line Items] | |||||
Goodwill impairment | $ 18,508,000 | $ 1,682,000 | |||
Goodwill | $ 0 | $ 0 | 18,508,000 | $ 20,190,000 | |
Discounted Future Cash Flow | |||||
Goodwill [Line Items] | |||||
Impairment analysis, weighted-average cost of capital | 14.00% | 19.00% | 14.00% | ||
Impairment analysis, perpetual growth rate | 3.00% | 2.00% | |||
Non-Cannabinoid | |||||
Goodwill [Line Items] | |||||
Goodwill impairment | $ 1,682,000 | $ 0 | 1,682,000 | ||
Goodwill | $ 0 | $ 0 | $ 0 | $ 0 | $ 1,682,000 |
X | ||||||||||
- Definition Impairment Analysis, Perpetual Growth Rate No definition available.
|
X | ||||||||||
- Definition Impairment Analysis, Weighted-average Cost of Capital No definition available.
|
X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|